Reuters Health News Summary

Following is a summary of current health news briefs. Israel's IceCure says gets FDA nod to treat tumors in liver, kidney

Israel's IceCure Medical said on Sunday it received U.S. regulatory approval to expand the use of its cryoablation technology to treat benign and cancerous tumors in livers and kidneys, sending its share price up 30%. IceCure's treatment uses special needles to inject liquid nitrogen to freeze and destroy tumors without the need for surgery. U.S. government says verdict in Bayer's Roundup case should be reversed

The U.S. Environmental Protection Agency and the Justice Department said a federal appeals court should reverse a lower court verdict finding Bayer AG liable in the case of a California man who blamed its Roundup weed killer for his cancer. The government said in a friend of the court brief filed on Friday that glyphosate, the weed killer's active ingredient, is not a carcinogen and as a result a warning on the label was not required as California state law demands. U.S. FDA declines to approve GSK drugs division's long acting HIV injection

GlaxoSmithKline's HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection. ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment's chemistry, manufacturing and controls process, but not its safety. Eisai Inc announces U.S. approval for insomnia drug

Japan-based drugmaker Eisai Co's U.S. subsidiary announced on Sunday that it had received approval from the U.S. Food and Drug Administration for its insomnia treatment in adult patients. The agency approved the drug, Dayvigo, in doses of 5 mg and 10 mg based on two late-stage studies testing the drug in patients with insomnia versus placebo for up to one month and six months, the drugmaker's U.S. subsidiary said.